Search results for " B-Cell"

showing 10 items of 207 documents

Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia

2004

In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome. Mutations of the BCL-6 gene are also observed in a subset of B-CLL, but the clinical significance of this molecular alteration remains uncertain. We examined the distribution of IgVH and BCL-6 gene mutations in 95 well-characterized patients with Binet stage A B-CLL, and correlated them with clinical, laboratory, cytogenetic findings and disease progression. Mutations of the BCL-6 gene were observed only in cases harboring mutated IgVH. Unexpectedly, coexistence of IgVH and BCL-6 mutations was co…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaImmunoglobulin Variable RegionLocus (genetics)BiologyGene mutationDisease-Free SurvivalGermline mutationProto-Oncogene ProteinsInternal medicinemedicineHumansB-cell chronic lymphocytic leukemiaClinical significanceProspective StudiesGeneAgedAged 80 and overHematologyChromosomes Human Pair 11HematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6FemaleChromosome DeletionChromosomes Human Pair 17Follow-Up StudiesTranscription FactorsLeukemia
researchProduct

Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: The InterLymph…

2014

Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are two subtypes of non-Hodgkin lymphoma. A number of studies have evaluated associations between risk factors and CLL/SLL risk. However, these associations remain inconsistent or lacked confirmation. This may be due, in part, to the inadequate sample size of CLL/SLL cases. Methods: We performed a pooled analysis of 2440 CLL/SLL cases and 15 186 controls from 13 case-control studies from Europe, North America, and Australia. We evaluated associations of medical history, family history, lifestyle, and occupational risk factors with CLL/SLL risk. Multivariate logistic regression analyses were used to estimate …

AdultMaleOncologymedicine.medical_specialtyCancer ResearchChronic lymphocytic leukemiaComorbidityArticleYoung AdultRisk FactorsOccupational ExposureInternal medicinehemic and lymphatic diseasesOdds RatiomedicineHumansMedical historyFamily historyYoung adultLife StyleAgedAged 80 and overbusiness.industryAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphomaEuropeOncologyCase-Control StudiesMeta-analysisNorth AmericaImmunologyFemalebusiness
researchProduct

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients…

2003

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab-CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment. Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications. One patient withdrew consent after achieving complete remission (CR) prior to HDT. One patient was taken off study with signs of disease progression after induction treatment. All patients showed stable engraftment after HDT. Re…

AdultMaleOncologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellCHOPTransplantation AutologousAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideImmunosuppression TherapyPeripheral Blood Stem Cell TransplantationTransplantationChemotherapybusiness.industryGraft SurvivalRemission InductionImmunityAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaSurgeryLymphomaTransplantationDoxorubicinVincristineFeasibility StudiesPrednisoneFemaleRadiotherapy AdjuvantMantle cell lymphomaRituximabRituximabbusinessmedicine.drugBone Marrow Transplantation
researchProduct

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leuke…

2014

Item does not contain fulltext In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on Q…

AdultMaleOncologymedicine.medical_specialtyTransplantation ConditioningRandomizationCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2][SDV]Life Sciences [q-bio]medicine.medical_treatmentChronic lymphocytic leukemiaHematopoietic stem cell transplantationTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansComputingMilieux_MISCELLANEOUSAgedbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cellhumanities3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisQuality of LifeFemaleTransplantation Conditioningbusiness030215 immunologyAmerican Journal of Hematology
researchProduct

ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study.

2012

Diffusion-weighted magnetic resonance imaging (DW-MRI) allows quantifying the random motion of water molecules in tissue by means of apparent diffusion coefficient (ADC) measurements. The aim of the study was to determine whether ADC measurements allow discrimination of diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL), and to examine the relationship between cellularity and ADC value of the tumor using DWI.Thirty-two patients with histologically proven non-Hodgkin lymphoma (21 with DLBCL and 11 with FL, 17 males and 15 females, mean age 62±13 years) underwent conventional MRI and DWI examination before treatment. The ADC values of DLBCL were compared to those of FL. The A…

AdultMalePathologymedicine.medical_specialtyBiopsyFollicular lymphomaContrast MediaMeglumineimmune system diseaseshemic and lymphatic diseasesBiopsymedicineOrganometallic CompoundsEffective diffusion coefficientHumansRadiology Nuclear Medicine and imagingIn patientProspective StudiesAgedAged 80 and overMegluminemedicine.diagnostic_testbusiness.industryta1182Magnetic resonance imagingGeneral MedicineMiddle Agedta3122medicine.diseaseLymphomabody regionsDiffusion Magnetic Resonance ImagingFemaleLymphoma Large B-Cell DiffuseNuclear medicinebusinessDiffuse large B-cell lymphomamedicine.drugEuropean journal of radiology
researchProduct

Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma.

1996

A particular type of lymphomatous bone marrow infiltration defined as intrasinusoidal and occuring in seven patients with splenomegaly and mild to moderate thrombocytopenia is reported. Immunocytochemistry highlighted the intrasinusoidal pattern and showed a mature B-cell phenotype. Four patients underwent splenectomy and a diagnosis of splenic marginal cell lymphoma was made. The disease course seems to be chronic and quite indolent. All patients are alive and well ; follow-up ranges from 2 to 42 months. The value of bone marrow biopsy as a primary diagnostic tool in splenic marginal zone lymphomas is discussed.

AdultMalePathologymedicine.medical_specialtyHistologyLymphoma B-Cellmedicine.medical_treatmentSplenectomySpleenPathology and Forensic MedicineImmunophenotypingSinusoidBone MarrowBiopsymedicineHumansAgedmedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsBone Marrow ExaminationGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistrymedicine.anatomical_structureImmunohistochemistryFemaleBone marrowSplenic diseaseSplenic LymphomabusinessHistopathology
researchProduct

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central …

2021

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reac…

AdultMalePathologymedicine.medical_specialtyLymphomaBiopsyConcordanceinterleukin-10diffuse large B-cell lymphomaMutation MissenseCentral Nervous System Neoplasms03 medical and health sciencesprimary CNS lymphoma0302 clinical medicineCerebrospinal fluidhemic and lymphatic diseasesBiopsyBiomarkers TumorTaqManmedicineHumansdiffuse large B-cell lymphoma interleukin-10 interleukin-6 MYD88 L265P mutation primary CNS lymphomaProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryinterleukin-6Primary central nervous system lymphomaHematologyMiddle Agedmedicine.diseaseInterleukin-10Neoplasm ProteinsLymphomaMYD88 L265P mutationAmino Acid Substitution030220 oncology & carcinogenesisMyeloid Differentiation Factor 88FemalebusinessDiffuse large B-cell lymphoma030215 immunologyBritish Journal of Haematology
researchProduct

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diff use large B-cell lymphoma: comparison b…

2015

Summary Background Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collab…

AdultMalePathologymedicine.medical_specialtyPediatricsAdolescent[SDV]Life Sciences [q-bio]Follicular lymphomaAutopsyNOminimum clinical recommendations03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicinefollow upHumans030212 general & internal medicineYoung adultcancer survivalLymphoma FollicularNon-Hodgkin lymphomaAgedHematologyWalesminimum clinical recommendations Non-Hodgkin lymphoma relative survival cancer survival follow upbusiness.industryCancerrelative survivalHematologyMiddle Agedmedicine.disease3. Good healthLymphoma[SDV] Life Sciences [q-bio]EuropeScotland030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaInternational Classification of Diseases for Oncology
researchProduct

Low incidence but poor prognosis of complicated coeliac disease: A retrospective multicentre study.

2013

Abstract Background Coeliac disease is a chronic enteropathy characterized by an increased mortality caused by its complications, mainly refractory coeliac disease, small bowel carcinoma and abdominal lymphoma. Aim of the study was to study the epidemiology of complications in patients with coeliac disease. Methods Retrospective multicenter case–control study based on collection of clinical and laboratory data. The incidence of complicated coeliac disease was studied among coeliac patients directly diagnosed in four Italian centres. Patients referred to these centres after a diagnosis of coeliac disease and/or complicated coeliac disease in other hospitals were therefore excluded. Results B…

AdultMalePediatricsmedicine.medical_specialtyPoor prognosisLymphoma B-CellSettore MED/09 - Medicina InternaComplicationsCELIAC DISEASEcomplicated coeliac diseaseKaplan-Meier EstimateGastroenterologyCoeliac diseaseNOCohort StudiesEnteropathy-Associated T-Cell LymphomaRefractoryCELIAC DISEASE; ComplicationsInternal medicineEpidemiologyIntestinal NeoplasmsIntestine SmallmedicinePrevalenceHumansAgedRetrospective StudiesHepatologybusiness.industryIncidence (epidemiology)IncidenceCarcinomaGastroenterologyCurve analysisnutritional and metabolic diseasesMiddle Agedmedicine.diseasePrognosisdigestive system diseasesLymphomaItalyAbdominal NeoplasmsCase-Control StudiesCohortFemalebusiness
researchProduct

Occupational exposure to immunologically active agents and risk for lymphoma: The European Epilymph case-control study

2013

Objectives: Allergies and asthma may be protective for the development of lymphoma. We evaluated whether occupational allergens that provoke immune reactivity and asthma through an IgE-mediated pathway are protective for lymphoma. Methods: The Epilymph study includes histologically or cytologically confirmed Hodgkin, B-cell, and T-cell lymphoma cases from six European countries (Spain, France, Germany, Italy, Ireland, and Czech Republic) recruited in 1998-2004. Controls were frequency matched to cases by age, gender, and study centre. Lifetime occupational exposure to seven high molecular weight (HMW) agents was evaluated through an asthma-specific job-exposure matrix. 2205 lymphoma cases a…

AdultMaleRiskCancer Researchmedicine.medical_specialtyAllergyLymphoma B-CellEpidemiologyHigh molecular weight exposuresLymphoma T-CellImmunoglobulin ELogistic regressionYoung Adultimmune system diseasesInternal medicinehemic and lymphatic diseasesEpidemiologyHypersensitivitymedicineHumansAsthma OccupationalYoung adultAgedAsthmabiologybusiness.industryCase-control studyAllergensImmunoglobulin EMiddle AgedOccupational exposuremedicine.diseaseHodgkin DiseaseLymphomaEuropeMolecular WeightOccupational DiseasesLogistic ModelsOncologyCase-Control StudiesImmunologybiology.proteinFemalebusinessCase–control
researchProduct